IQV compared with MXCT: revenue, margins and what each company keeps, and the suppliers and customers both name

IQVIqvia Holdings Inc.

Mkt capRevenueRevenue

MXCTMaxcyte, Inc.

Mkt capRevenueRevenue

Compare

IQVIqvia Holdings Inc.

MXCTMaxcyte, Inc.

Price

Mkt cap

Revenue

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Save comparison

Revenue flow

News Findings Companies A–Z Pricing Methodology Sources Corrections About Terms

Not investment advice. Not a broker-dealer. Indices shown as ETF proxies. Supply-chain data CC BY 4.0; market data not redistributable.

Listed on One’s Vibe · live-checked · Oct ’26

Desk News Calendar Saved

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Price

Supply-chain overlap

Revenue flow

MXCT: latest quarter is a loss; flow not drawable.Method ›

Price

rebased to 0%

IQV, solidMXCT, dashed

Supply-chain overlap

direct ties · both sidesSources ›

direct ties · both sides

Only IQV 1

VSTMVerastemcustomer

Shared 0

No shared counterparties.

Only MXCT 5

TGTXTG Therapeuticscustomer

DTILPrecision BioSciencescustomer

—SeQure Dxunlistedsupplier

—Imugene (USA)

Role chip = supplier or customer—= no ticker (unlisted)Source: SEC EDGAR

unlistedcustomer

1 more · MXCT chain ›

IQVIqvia Holdings Inc.

262.25▲+1.48%· post 262.25

Mkt cap$42.6BRevenue$4.4BQ3 FY26Revenue$16.3BFY25

MXCTMaxcyte, Inc.

1.44▼−0.45%· post 1.44

ClosedNov 3 '26

Mkt cap$150.7MRevenue$7MQ2 FY26Revenue$33MFY25

Compare

ClosedNov 3 '26

IQVIqvia Holdings Inc.

MXCTMaxcyte, Inc.

262.25▲+1.48%post 262.25

Price

1.44▼−0.45%post 1.44

$42.6B

Mkt cap

$150.7M

Q3 FY26$4.4B

Revenue

$7MQ2 FY26

FY25$16.3B

Revenue

$33MFY25

IQV262.25▲+1.48%vsMXCT1.44▼−0.45%ClosedNov 3 '26